Payment overview · 2025
General Payments
$214.57
11 reported records · 6 companies
Healthcare provider profile · identity verified
Kauser Yasmeen, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HICKSVILLE, NY · NPI 1679519656
Verified facts
What the public records show
CMS Open Payments records show Kauser Yasmeen, MD received $214.57 in general payments during 2025 across 11 reported records.
AstraZeneca Pharmaceuticals LP accounted for 35.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $77.12 | 35.9% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.63 | 21.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.30 | 13.7% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.85 | 11.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.42 | 10.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.25 | 7.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $214.57 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $77.12 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $29.30 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $27.10 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $27.10 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.85 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.42 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 178 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 123 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 56 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
123 | 29 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
34 | 34 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
178 | 40 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 601 | 189 |
| Amlodipine Besylate | Amlodipine Besylate | 428 | 141 |
| Levothyroxine Sodium | Levothyroxine Sodium | 373 | 98 |
| Metformin Hcl | Metformin Hcl | 309 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 298 | 99 |
| Furosemide | Furosemide | 212 | 72 |
| Gabapentin | Gabapentin | 198 | 69 |
| Losartan Potassium | Losartan Potassium | 191 | 64 |
| Metoprolol Tartrate | Metoprolol Tartrate | 191 | 59 |
| Simvastatin | Simvastatin | 186 | 52 |
| Eliquis | Apixaban | 178 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 158 | 47 |
| Lisinopril | Lisinopril | 154 | 41 |
| Omeprazole | Omeprazole | 153 | 55 |
| Potassium Chloride | Potassium Chloride | 139 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 137 | 30 |
| Mirtazapine | Mirtazapine | 135 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 135 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 128 | 31 |
| Atenolol | Atenolol | 125 | 35 |
| Farxiga | Dapagliflozin Propanediol | 123 | 29 |
| Famotidine | Famotidine | 117 | 58 |
| Prednisone | Prednisone | 116 | 65 |
| Alprazolam | Alprazolam | 114 | 31 |
| Enalapril Maleate | Enalapril Maleate | 112 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 110 | 35 |
| Januvia | Sitagliptin Phosphate | 99 | 30 |
| Sertraline Hcl | Sertraline Hcl | 92 | 23 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 89 | 33 |
| Donepezil Hcl | Donepezil Hcl | 84 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 80 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 80 | 46 |
| Tramadol Hcl | Tramadol Hcl | 77 | 28 |
| Trazodone Hcl | Trazodone Hcl | 77 | 32 |
| Azithromycin | Azithromycin | 76 | 59 |
| Fluoxetine Hcl | Fluoxetine Hcl | 72 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 67 | 21 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 66 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 21 |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 65 | 59 |
| Torsemide | Torsemide | 62 | 13 |
| Xarelto | Rivaroxaban | 61 | 18 |
| Montelukast Sodium | Montelukast Sodium | 60 | 22 |
| Buspirone Hcl | Buspirone Hcl | 58 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 19 |
| Finasteride | Finasteride | 57 | 16 |
| Ozempic | Semaglutide | 57 | 14 |
| Jardiance | Empagliflozin | 56 | 15 |
| Hydrocortisone | Hydrocortisone | 54 | 28 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 54 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 54 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 52 | 27 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | 13 |
| Tradjenta | Linagliptin | 50 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 13 |
| Allopurinol | Allopurinol | 44 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 17 |
| Glimepiride | Glimepiride | 44 | 15 |
| Sucralfate | Sucralfate | 44 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 41 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 39 | 14 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 37 | 22 |
| Meclizine Hcl | Meclizine Hcl | 37 | 22 |
| Sodium Chloride | 0.9 % Sodium Chloride | 37 | 24 |
| Valsartan | Valsartan | 37 | 14 |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Memantine Hcl | Memantine Hcl | 35 | 11 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 34 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 34 | 11 |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 21 |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Nystatin | Nystatin | 30 | 19 |
| Methimazole | Methimazole | 29 | suppressed |
| Budesonide | Budesonide | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 18 |
| Carvedilol | Carvedilol | 25 | 14 |
| Meloxicam | Meloxicam | 24 | 17 |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Lactulose | Lactulose | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 19 |
| Fycompa | Perampanel | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | 12 |
| Clonazepam | Clonazepam | 21 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Metolazone | Metolazone | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | 13 |
| Phenobarbital | Phenobarbital | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Xcopri | Cenobamate | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Repaglinide | Repaglinide | 18 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 18 | suppressed |
| Verapamil Sr | Verapamil Hcl | 18 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | 11 |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 16 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Dexamethasone | Dexamethasone | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Phenytoin | Phenytoin | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 13 | 11 |
| Digoxin | Digoxin | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 13 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Imiquimod | Imiquimod | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $214.57 · 11 records | AstraZeneca Pharmaceuticals LP | ELIQUIS, FARXIGA, GEMTESA, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error